



CASE 4-32303A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 731063910 US  
Express Mail Label Number

May 10, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

DIXON ET AL.

APPLICATION NO: 10/525,456

FILED: FEBRUARY 24, 2005

FOR: HB-954 AS A TARGET FOR MODULATING ANGIOGENESIS


MS: Missing Parts  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUBMISSION OF SEQUENCE LISTING  
INCLUDING STATEMENT OF VERIFICATION

In response to the Office Action of March 31, 2006, Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are the same, and include no new matter.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346

  
John T. Prince  
Attorney for Applicants  
Reg. No. 43,019

Date: May 10, 2006